Type in a keyword and see the report right away. Explore your online world!
If you have already a Newsmeter account:
You can free sign up for Newsmeter:
x
A subgroup of patients from the 3 CARTITUDE trials experienced cranial nerve palsy after treatment, most of whom were men.
Findings from the phase 3 CARTITUDE-4 trial support the European approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Loncastuximab tesirine and rituximab led to encouraging responses in most patients with relapsed/refractory follicular lymphoma in a single-center study.
'Off the shelf' CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of Evidence-Based Oncology.
Sandip Patel, MD, presents a case study of a 62-year-old female patient with a PD-L1 expression of 60%, an EGFR exon 20 insertion mutation, and liver lesions, followed by a panel discussion on diagnostic strategies to optimize patient care.
Christine Bestvina, MD, presents her treatment strategy for a 62-year-old female with NSCLC, bone and liver metastases, and an EGFR exon 20 insertion; the panel then assesses clinical data, including the MARIPOSA trial, to guide their treatment decisions.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Researchers from MSKCC have explored the potential of personalized fludarabine dosing, based on population pharmacokinetics, to enhance the outcomes of CD19 CAR T-cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphomas.
Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.
Findings from the CheckMate-901 trial support the CHMP’s positive opinion of nivolumab plus chemotherapy in metastatic urothelial carcinoma.
A verbal tocilizumab workflow helped provide safer and more effective delivery of the agent for patients experiencing cytokine release syndrome.
Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.
Nitin Jain, MD, presents data on the efficacy of various chronic lymphocytic leukemia treatments, reviews current guidelines, discusses the increasing use of Bruton's tyrosine kinase inhibitors and the decreasing role of chemotherapy in his practice. He emphasizes the importance of considering patient factors and preferences in treatment decision-making.
One of the most important roles of a nurse coordinator is transmitting patient and caregiver information during the CAR T-cell treatment process.
Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.
